Last updated on December 2019

A Study Evaluating the Efficacy and Safety of the LentiGlobin BB305 Drug Product in Subjects With Transfusion-Dependent -Thalassemia


Brief description of study

This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 subjects 50 years of age with transfusion-dependent -thalassemia (TDT), who have a 0/0, 0/IVS-I-110, or IVS-I-110/IVS-I-110 genotype. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.

Clinical Study Identifier: NCT03207009

Find a site near you

Start Over